(2023)
Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/pertuzumab for HER2-positive breast cancer.
BREAST.
72,
(2023)
Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16).
EUROPEAN JOURNAL OF CANCER.
195,
(2023)
Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
JAMA NETWORK OPEN.
6,
11
(2023)
A Retrospective Exploratory Analysis for Serum Extracellular Vesicles Reveals APRIL (TNFSF13), CXCL13, and VEGF-A as Prognostic Biomarkers for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.
24,
21
(2023)
Impact of high dose radiotherapy for breast tumor in locoregionally uncontrolled stage IV breast cancer: a need for a risk-stratified approach.
RADIATION ONCOLOGY.
18,
1
(2023)
Comprehensive Clinical Characterization of Decade-Long Survivors of Metastatic Breast Cancer.
CANCERS.
15,
19
(2023)
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.
LANCET ONCOLOGY.
24,
9
(2023)
Pretreatment endocrine symptoms and recurrence-free survival among young premenopausal patients with breast cancer: a prospective cohort study.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY.
15,
(2023)
Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer.
GENOME MEDICINE.
15,
1
(2023)
Comparison of initial and sequential salvage brain-directed treatment in patients with 1–4 vs. 5–10 brain metastases from breast cancer (KROG 16–12).
BREAST CANCER RESEARCH AND TREATMENT.
200,
1
(2023)
Progesterone Receptor Expression Level Predicts Prognosis of Estrogen Receptor-Positive/HER2-Negative Young Breast Cancer: A Single-Center Prospective Cohort Study.
CANCERS.
15,
13
(2023)
Real World Experience of Second-Line Treatment Strategies after Palbociclib and Letrozole: Overall Survival in Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
CANCERS.
15,
13
(2023)
Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancer.
SCIENTIFIC REPORTS.
13,
1
(2023)
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
NEW ENGLAND JOURNAL OF MEDICINE.
388,
22
(2023)
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer.
ESMO OPEN.
8,
3
(2023)
Diagnostic Value of FDG PET/CT in Surveillance after Curative Resection of Breast Cancer.
CANCERS.
15,
9
(2023)
Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment.
FUTURE ONCOLOGY.
19,
8
(2023)
Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1).
BREAST CANCER.
30,
3
(2023)
Preliminary Attainability Assessment of Real-World Data for Answering Major Clinical Research Questions in Breast Cancer Brain Metastasis: Framework Development and Validation Study.
JOURNAL OF MEDICAL INTERNET RESEARCH.
25,
-
(2022)
Data collection framework for electronic medical record-based real-world data to evaluate the effectiveness and safety of cancer drugs: a nationwide real-world study of the Korean Cancer Study Group.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY.
14,
-
학술회의논문
(2012)
Effects of Statin on triple-negative breast cancer(TNBC) with Ets-1 overexpression.
San Antonio Breast Cancer Syposium.
미국
(2012)
Validation and comparison of CS-IHC4 score with a nomogram based on Ki67 index, Adjuvant! Online, and St. Gallen risk stratification to predict recurrence in early Hormone Receptor(HR)-positive brease cancers.
San Antonio Breast Cancer Syposium.
미국
(2012)
Quality of life (QoL) in Metastatic Breast Cancer Patients with Maintenance Paclitaxel plus Gemcitabine (PG) Chemptherapy: Rwsults from Phase III, Multicenter, Randomized Trial of Maintenance Chemotherapy Versus Observation.
한국임상암학회 제5차 학술대회.
대한민국
(2012)
A Phase III, Multicenter, randomized Trial of Maintenance Versus Observation After Achieving Clinical Response in Patients With Metastatic Breast cancer Who Received 6 Cycles of Gemcitabine Plus Paclitaxel as First-line Chemotherapy.
The 10th Annual Meeting of JSMO.
일본
(2012)
Time to brain metastasis(TTBM) from initial diagnosis of distant metastasis in breast cancer: Prediction of TTBM according to breast cancer subtypes ans treatment effect.
The 10th Annual Meeting of JSMO.
일본
(2011)
Adjuvant Trastuzumab Effect on HER2-Positive Breast Cancers
According to Hormonal Receptor (HR) Status: Crosstalk between ER and EGFR/HER2 Pathway May Prevent Trastuzumab from Improving Outcomes in HER2-Positive and HR-Positive Breast Cancers..
Cancer Research.
미국
(2011)
Nomogram To Predict Recurrence and To Avoid Unnecessary
Adjuvant Chemotherapy Based on Ki67 Index and ER Status
in Hormone Receptor (HR)-Positive Breast Cancers with Low
Number of Nodal Metastases (≤3) (NCT01273415).
Cancer Research.
미국
(2011)
Small Node-Negative (T1b-cN0) Invasive Hormone Receptor
(HR)-Positive Breast Cancers: Is There a Population Which Might
Have Benefit from Adjuvant Chemotherapy?.
Cancer Research.
미국
(2011)
Abjuvant Trastuzumab Effect on HER2-Positive Breast Cancers According to Hormonal Receptor(HR)State: Cross-talk between HER2 and ER pathway May Prevent Trastuzumab from Improving Outcomes in HER2+ve/HR+ve Breast Cancers.
한국임상암학회지.
대한민국
(2011)
Small Node-Negative(T1b-cNO) Invasive Hormone Receptor (HR)-Positive Breast Cancers: Is there a population which might have benefit from adjuvant chemotherapy?.
한국임상암학회지.
대한민국
(2011)
Comparison The Nomogram to Other Predictive Tolls (Adjuvant! Online,St.Galen Consensus,And CS-IHC4) In Hormone Receptoe (HR)-Positive Breast Cancers.
Journal of Breast Cancer.
대한민국
(2011)
Proposal of a Breast Cancer-Specific Prognostic Model And a Nomogram to Predict Outcomes for with Brain Metastates(BM) From Breast Cancer.
Journal of Breast Cancer.
대한민국
(2011)
CA 15-3 Elevations According to Breast Cancer Subtypes at Initial Diagnosis of Metastatic Breast Cancer (MBC).
Cancer Research and Treatment.
대한민국
(2011)
Fluropyrimidine/platinum-based First-line Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma: Prognostic Factor Analysis in 239 Patients.
Cancer Research and Treatment.
대한민국
(2011)
Prognostic Impact on FOXP3 Expression in Triple Negative Breast Cancer (TNBC).
CANCER RESEARCH AND TREATMENT.
대한민국
(2011)
Prognostic Model for Patients with Brain Metastases (BM) from Breast Cancer.
CANCER RESEARCH AND TREATMENT.
대한민국
(2011)
Prognostic impact on FOXP3 expression in triple-negative breast cancer (TNBC)..
Journal of Clinical Oncology.
미국
(2011)
Prognostic index for patients with brain metastases from breast cancer: A validation and refinement of the breast-specific graded prognostic assessment (GPA) index.
Journal of Clinical Oncology.
미국
(2010)
Differences of Clinical Manifestataions and Therapeutic Outcomes in Leptomeningeal Metastases (LM) According to Breast Cancer Subtypes..
Cancer Research.
미국
(2010)
Thymidylate Synthase (TS) and Thymidine Phosphorylase (TP ) Exprssion as Predictive Markers of Capecitabine Mono-Chemotherapy for Patients with Anthracyclin-Taxane Pretreated Metastatic Breast Cancer(MBC)..
Cancer Research.
미국
